Your nerves deliver electrical messages between your brain and nerves, some of which may be misinterpreted as pain signals. Enso uses safe electric pulses to stop these messages being transmitted and provide pain relief.
Hinge Health will acquire a non-invasive electrical stimulation device that has been demonstrated through clinical studies to provide immediate and clinically effective pain management, adding it into its Digital MSK Clinic for employer and health plan clients.
Non-addictive
This study, published in Journal of Pain Research, randomly assigned participants either an electrical impulse device or a sham device. Users in the treatment group used mobile apps to adjust device settings such as pulse duration and intensity; HIPAA-compliant chat features were also included within these apps and participants were contacted three times weekly by study coordinators to resolve issues that arose during treatment. Meanwhile, the sham device displayed LED light animations simulating actual pulse delivery but without actually administering treatment pulses.
Both groups received identical treatment protocols and amounts of therapy, and results from both studies demonstrated a significant increase in back pain reduction and mobility improvement with use of electrical stimulation versus placebo devices – similar to what had been seen previously clinical trials that proved it improved back pain and function; and these results add further evidence supporting its use for pain management.
Health tech companies are making strides in the MSK space, with Omada and DarioHealth raising millions from investors while virtual MSK care services like Sword Health, Kaia Health, Sparta Science and SpineZone receiving investor interest. But these digital MSK solutions are still relatively unproven as most employers and health plans only just starting to explore them.
Hinge has thus acquired Enso, a wearable that provides long-term pain relief through electrical nerve stimulation. Invented by Shaun Rahimi – an engineer who experienced excruciating back pain himself – who developed this solution to avoid surgery or medications.
Enso is an FDA-cleared TENS (transcutaneous electrical nerve stimulation) device, meaning that it sends safe pulses across your skin to relieve pain. Your nerves carry electrical messages between your brain and skin that sometimes misfire about pressure and temperature resulting in discomfort. Enso uses the same technology used by doctors for decades to reduce pain – drug-free devices known as TENS have proven 2x more effective than opioid pain relievers at improving mobility; also shortening disability leave to return employees sooner, helping employees return sooner while avoiding unnecessary opioid prescriptions.
Adaptive
Enso’s innovative TENS device continuously monitors pain levels and adjusts stimulation patterns accordingly, giving long-lasting relief without low-frequency pulses or surgical implants that require implantation. Furthermore, the Enso can be worn under clothing as opposed to invasive pain relief implants that must be implanted under your skin – unlike these implants! Furthermore, this device can treat upper and lower back pain; however it should not be used on neck pain, pregnant women, or people suffering severe epilepsy.
Enso’s FDA-cleared algorithm adapts stimulation patterns based on your specific pain level, making it highly effective at relieving discomfort. Furthermore, Enso can also help reduce disability and shorten return-to-work time while already being covered by workers’ compensation insurers and veterans hospitals – making it an invaluable asset for employers or health plans looking to enhance worker’s compensation claims.
Recent clinical research on the HFIT device demonstrated its superior effectiveness at alleviating back pain and increasing mobility, as measured by Six-Minute Walk Test and Timed Up and Go testing. Participants randomly allocated real devices reported significant reductions in pain and mobility issues measured through tests like Six-Minute Walk Test or Timed Up and Go testing, along with greater decreases in work disability than those in sham control group.
This study marks the first evidence-based test demonstrating a wearable device can offer sustained, durable pain relief in patients suffering chronic Musculoskeletal (MSK) conditions. While previous research had demonstrated low-frequency electrical nerve stimulation can alleviate discomfort, this one shows high-frequency impulse therapy can have lasting benefits as well as increasing functional mobility for chronic low back pain sufferers. While initial results seem promising, larger testing should still take place; employers and health plans may wish to incorporate this new technology into MSK care programs for improved care outcomes.
Convenient
Recent randomized clinical trial data demonstrated the device to provide pain relief three times faster than opioids and improve mobility by two times faster. Over time, the device can adapt to meet individual needs – this process is known as learning.
Enso is designed to work with your body’s natural electrical signals by administering safe impulses through the skin that provide pain-relief without side effects – meaning no adverse side effects due to drug-free stimulation of muscles by Enso.
Hinge Health has already shown its commitment to digital musculoskeletal care with M&A deals involving Oska Wellness and DarioHealth, but now its portfolio expands by purchasing Enso, an easy-to-use noninvasive electric nerve stimulation pain-relief wearable device without surgical implantation that is noninvasive electric nerve stimulation pain relief device that requires no surgical implantation and provides full day pain relief when worn for four hours a day – being covered under workers’ compensation and veterans affairs insurers nationally as per product page by Enso as stated on product page by Hinge itself as part of its portfolio investment plans in Enso’s growth plans in future investments made into it’s development by investing further investments by making further investments into its continued investment into its development as it grows into Hinge.
Strong
Enso e-stim uses high-frequency electrical pulses to block pain signals from reaching the brain and alter nerve ionic balances involved in processing these signals – this process is known as depolarization and trains the neurons differently to respond to pain. This can aid neuromuscular rehabilitation. Furthermore, it may reduce involuntary muscle spasms that often accompany chronic conditions like plantar fasciitis. Finally, it may reduce foot and heel pain which makes walking difficult or impossible. E-stim therapy is a noninvasive solution suitable for most people, including diabetic patients and pregnant women. Suitable for use at home or clinic, its noninvasive design makes it suitable for treating various symptoms including fibromyalgia, rheumatoid arthritis and osteoarthritis, in addition to sciatica and carpal tunnel syndrome pain relief as well as migraine relief.
Hinge Health is continuing its investment in digital musculoskeletal (MSK) care by acquiring Enso, which has been clinically shown to reduce pain without side effects. Hinge will add the Enso device as part of their Digital MSK Clinic offering for employer clients as well as making it freely available for membership at no extra cost.
This FDA-cleared wearable device provides noninvasive and nonaddictive pain relief via high-frequency impulses known to increase blood flow to affected areas and reduce inflammation. A randomized controlled trial confirmed this device significantly reduced pain while increasing mobility among participants compared with control group participants.
Enso is designed for ease of use, featuring a small device that easily fits on your body. Rechargeable and without adhesive gel pads or wiring invasiveness, Enso makes exercise comfortable while staying within its recommended parameters; however it should not be worn above the neck nor by people suffering severe epilepsy or seizures.
Double-blind clinical trials conducted with this device have demonstrated its efficacy to reduce pain by 56% and provide clinically effective relief to 86% of those experiencing lower back pain. Furthermore, its ability to shorten disability time has helped workers’ compensation claimants return sooner to work, as well as being easy for daily use without significant side effects or side effects.
